Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Momenta/Sandoz Tie-Up Adds Momentum to Large Molecules

This article was originally published in Start Up

Executive Summary

The July 2006 alliance between Momenta Pharmaceuticals and Novartis AG's generics outfit Sandoz underscores the role sugar characterization technologies may play in both copying complex molecules like follow-on biologics and improving on existing glycoproteins and complex mixtures.
Advertisement

Related Content

Ambrx Takes Advantage of Large Molecule Frenzy
Ambrx Takes Advantage of Large Molecule Frenzy
The Large Molecule Future
The Large Molecule Future
A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric
A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091300

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel